SCHEMBL3672133

SCHEMBL3672133

COCCN1CCC(CC(OC(=O)N2CCN(c3ccc(OC)cc3)CC2)C2CCN(CCOC)CC2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 1/20 0.50
L3MBTL1 Q9Y468 2/20 0.48
ALDH1A1 P00352 2/20 0.46
GAA P10253 1/20 0.46
TSHR P16473 1/20 0.44
ATM Q13315 1/20 0.44
DRD2 P14416 3/20 0.44
HTR2A P28223 2/20 0.44
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
DRD3 P35462 2/20 0.43
ADRB1 P08588 1/20 0.42
HTR2B P41595 1/20 0.42
SIGMAR1 Q99720 1/20 0.42
MAPK1 P28482 1/20 0.42
MAPT P10636 1/20 0.41
GFER P55789 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HTR1A P08908 1/20 0.41
DRD4 P21917 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3665697 0.91 GPR119 (0.47) GPR119L3MBTL1ALDH1A1GAATSHR
SCHEMBL314082 0.82 L3MBTL1 (0.54) GPR119L3MBTL1ALDH1A1GAATSHR
SCHEMBL4344165 0.79 ALDH1A1 (0.50) GPR119L3MBTL1ALDH1A1GAATSHR
SCHEMBL313990 0.73 MAPT (0.48) GPR119L3MBTL1ALDH1A1GAATSHR
SCHEMBL19099996 0.73 DRD2 (0.73) ALDH1A1DRD2HTR2AKMT2AMEN1
SCHEMBL314754 0.72 CHRM4 (0.57) GPR119ALDH1A1GAAMAPT
SCHEMBL315197 0.72 CHRM4 (0.48) GPR119GAADRD2KMT2AMAPK1
SCHEMBL314976 0.72 CHRM4 (0.52) GPR119SIGMAR1SMN1; SMN2HTR1A
Hydrochloric Acid SCHEMBL314118 0.71 CHRM4 (0.56) GPR119ALDH1A1GAAMAPT
Hydrochloric Acid SCHEMBL314653 0.71 CHRM4 (0.47) GPR119ALDH1A1GAATSHRDRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2234992-A2 PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS AstraZeneca AB (SE) 2010-10-06 EP disclosed
US-20090281087-A1 Compounds II BIOVITRUM AB (SE) 2009-11-12 US disclosed
WO-2009071668-A2 PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS BIOVITRUM AB (PUBL) (SE) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281087-A1 Compounds II GPR119, FABP4, LIPC GPR119 1/4885L3MBTL1 4693/4885ALDH1A1 2717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.